Hama Naoki, Marubashi Shigeru, Dono Keizo, Kobayashi Shogo, Kim Chiwan, Asaoka Tadafumi, Takeda Yutaka, Nagano Hiroaki, Umeshita Koji, Monden Morito, Doki Yuichiro, Mori Masaki
Dept. of Surgery, Graduate School of Medicine, Osaka University.
Gan To Kagaku Ryoho. 2008 Nov;35(12):2092-5.
We report a case of hepatocellular carcinoma (HCC) recurrence after the patient received a living donor liver transplantation, which was treated by combined modality therapy. The patient survived for 67 months. A 61-year-old male was diagnosed as HCC with alcoholic cirrhosis and was transplanted the liver from a living donor. The number of tumors was about 50, the maximum tumor size was 3.3 cm and histology of the tumor was poorly differentiated hepatocellular carcinoma with portal invasion (Vp2). HCC recurred at the peritoneum 12 months after the liver transplantation and was surgically resected. Then, multiple HCC recurred in the liver graft and the patient was treated by systemic chemotherapy, and local therapy such as RFA, PEIT and TAE. Now 67 months after the transplantation, he additionally has a HCC metastasis to the spleen and lung and is treated by combined modality therapy. This case suggested that a combined modality therapy might have improved the survival of the patient after recurrence in the liver transplantation for advanced HCC.
我们报告了1例肝细胞癌(HCC)患者在接受活体肝移植后复发,并接受了综合治疗的病例。该患者存活了67个月。一名61岁男性被诊断为患有酒精性肝硬化的HCC,并接受了来自活体供体的肝脏移植。肿瘤数量约为50个,最大肿瘤直径为3.3 cm,肿瘤组织学为伴有门静脉侵犯(Vp2)的低分化肝细胞癌。肝移植后12个月,HCC在腹膜复发并接受了手术切除。随后,肝移植肝内出现多处HCC复发,患者接受了全身化疗以及诸如射频消融(RFA)、经皮无水乙醇注射治疗(PEIT)和经动脉栓塞化疗(TAE)等局部治疗。目前,移植后67个月,他还出现了HCC转移至脾脏和肺部,并接受了综合治疗。该病例提示,对于晚期HCC肝移植术后复发的患者,综合治疗可能改善了其生存情况。